Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success

Am J Gastroenterol. 2023 Feb 1;118(2):360-363. doi: 10.14309/ajg.0000000000002085. Epub 2022 Oct 11.

Abstract

Introduction: Increasing antimicrobial resistance with Helicobacter pylori infection has focused efforts to tailor eradication therapy based on identifying genetic markers of resistance to predict antimicrobial susceptibility.

Methods: In this retrospective study, we report the effect of routine inclusion of antimicrobial susceptibility testing and recommendations for eradication therapy with gastric specimens with H. pylori .

Results: The use of a recommended treatment regimen based on genetic markers of resistance was associated with an 84% rate of eradication success and 4.4 greater odds of eradication relative to unrecommended treatment.

Discussion: This is the first study describing the use of H. pylori genetic resistance testing as standard of care.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clarithromycin / therapeutic use
  • Drug Resistance, Bacterial / genetics
  • Drug Therapy, Combination
  • Genetic Markers
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / genetics
  • Helicobacter pylori* / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Genetic Markers
  • Clarithromycin